Secondary Hyperparathyroidism

CKD-MBD Tied to Malnutrition-Inflammation Complex Syndrome

Publish Date May 12, 2022

A new review highlights the need to simultaneously control CKD-MBD and MICS in patients receiving hemodialysis.

Therapies to Slow Vascular Calcification in CKD Explored

Publish Date May 9, 2022

Promising therapies still need to be further evaluated in clinical trials.

Etelcalcetide vs Cinacalcet Treatment Adherence Examined

Publish Date May 9, 2022

Secondary hyperparathyroidism remains uncontrolled in many patients with chronic kidney disease.

Earlier Calcimimetic Use May Allow Better PTH Control in Hemodialysis

Publish Date May 5, 2022

Recent studies have shown the importance of starting treatment at lower phosphorus and PTH levels on long-term outcomes of SHPT.

Parathyroidectomy Increasing in the United States

Publish Date April 12, 2022

Despite the increasing availability of calcimimetics, parathyroidectomy rates in the US have gradually increased.

Post-Parathyroidectomy Hypocalcemia Risk Factors Identified

Publish Date April 12, 2022

Patients at risk for postoperative hypocalcemia need more vigilant postoperative monitoring.

Alendronate Protects Against Bone Loss in Kidney Transplant Recipients

Publish Date April 11, 2022

Decrease in bone mass is common in the first 6 to 12 months after kidney transplantation.

Electrolyte Abnormalities Common in Solid Organ Transplant Recipients

Publish Date April 11, 2022

Hypercalcemia was common among kidney transplant recipients at 3 months, investigators reported.

CKD-MBD Marker Changes Vary Across Dialysis Modalities

Publish Date March 15, 2022

Use of home dialysis and modalities other than conventional in-center hemodialysis is expected to grow.

Etelcalcetide Effective in Cases Where Cinacalcet Is Problematic

Publish Date March 11, 2022

Switching from oral to intravenous calcimimetic may lower PTH levels in patients on hemodialysis with poor tolerance.